Selected series of patients with localized Hodgkin's disease treated with different radiation fields.
| Radiation Field . | Center (ref) . | Patients . | No. of Patients . | DFS . | Survival . | @ Years* . |
|---|---|---|---|---|---|---|
| Involved Field | MD Anderson (7) | PS I and II (A and B) | 87 | 54% | — | 10 |
| CS I and II (A and B) | 133 | 35% | — | 10 | ||
| BNLI (3) | PS I and IIA | 107 | 54% | 81% | 10 | |
| Mantle Field | BNLI (3) | PS I and IIA | 212 | 57% | 79% | 10 |
| Melbourne (8) | CS I and II (A and B) | 64 | 46% | 89% | 5 | |
| PS I and II (A and B) | 66 | 67% | 90% | 5 | ||
| EORTC (5) | CS I and II (A and B) | 152 | 38% | 60% | 12 | |
| Toronto (4) | CS I and IIA | 121 | ∼62% | 10 | ||
| Extended Mantle | Boston (9) | PS I and IIA | 108 | 74% | 89% | 5 |
| Chicago (10) | PS I and IIA | 92 | 77% | 71% | 10 | |
| EORTC (5) | CS I and II (A and B) | 108 | 63% | 80% | 7 | |
| STNI/TNI | Stanford (11) | PS I and II (A and B) | 109 | 77% | 84% | 10 |
| Denmark (12) | PS I and II (A and B) | 133 | 90% | 90% | 7 | |
| Abbreviations: DFS, disease-free survival; PS, pathological stage (laparotomy-staged); CS, clinical stage; BNLI, British National Lymphoma Investigation; EORTC, European Organization for Research and Treatment of Cancer; STNI, subtotal nodal irradiation; TNI, total nodal irradiation | ||||||
| Radiation Field . | Center (ref) . | Patients . | No. of Patients . | DFS . | Survival . | @ Years* . |
|---|---|---|---|---|---|---|
| Involved Field | MD Anderson (7) | PS I and II (A and B) | 87 | 54% | — | 10 |
| CS I and II (A and B) | 133 | 35% | — | 10 | ||
| BNLI (3) | PS I and IIA | 107 | 54% | 81% | 10 | |
| Mantle Field | BNLI (3) | PS I and IIA | 212 | 57% | 79% | 10 |
| Melbourne (8) | CS I and II (A and B) | 64 | 46% | 89% | 5 | |
| PS I and II (A and B) | 66 | 67% | 90% | 5 | ||
| EORTC (5) | CS I and II (A and B) | 152 | 38% | 60% | 12 | |
| Toronto (4) | CS I and IIA | 121 | ∼62% | 10 | ||
| Extended Mantle | Boston (9) | PS I and IIA | 108 | 74% | 89% | 5 |
| Chicago (10) | PS I and IIA | 92 | 77% | 71% | 10 | |
| EORTC (5) | CS I and II (A and B) | 108 | 63% | 80% | 7 | |
| STNI/TNI | Stanford (11) | PS I and II (A and B) | 109 | 77% | 84% | 10 |
| Denmark (12) | PS I and II (A and B) | 133 | 90% | 90% | 7 | |
| Abbreviations: DFS, disease-free survival; PS, pathological stage (laparotomy-staged); CS, clinical stage; BNLI, British National Lymphoma Investigation; EORTC, European Organization for Research and Treatment of Cancer; STNI, subtotal nodal irradiation; TNI, total nodal irradiation | ||||||
Time point for DFS and overall survival